1
|
Colavitto B, Allen S, Winocur D, Dussaillant A, Guillet S, Muñoz-Torrero Manchado A, Gorsic S, Stoffel M. A glacial lake outburst floods hazard assessment in the Patagonian Andes combining inventory data and case-studies. Sci Total Environ 2024; 916:169703. [PMID: 38228238 DOI: 10.1016/j.scitotenv.2023.169703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Revised: 12/11/2023] [Accepted: 12/24/2023] [Indexed: 01/18/2024]
Abstract
We present a glacial-related lake inventory for a region spanning 41.5° - 47° S in Patagonian Andes, where information on past glacier lake outburst floods (GLOF's) has hitherto remained significantly underreported. Analyzing remotely sensed images, we obtained data on 702 glacial-related lakes. Through detailed geomorphic assessments and manual supervision, we revised current inventories and added 35 GLOFs triggered from moraine/bedrock dammed lakes failures. The regional GLOF inventory presented contains information on 71 historical failures of moraine/bedrock dammed glacial lakes. From this database we analyzed outburst timing and managed to constrain 37 events occurrences within a period of 1 year. Around 40 % of them have occurred since the early 2000's, most of them originating from lakes probably formed as a delayed response to the glacial retreat imposed by the end of the Little Ice Age. On the other hand, we analyzed meteorological conditions for a sub-set of 10 events constrained within a 10-days period, finding a strong link between atmospheric rivers, cut-off lows impacting the southern Andes, and GLOFs. Only one case is likely to have been triggered by a Mw 4.9 earthquake. Based on topographic potential for avalanching, we estimated GLOF hazard potential, recognizing at least 3 subregions with high hazard, which moreover can be highly susceptible to climate conditions that regionally affect GLOF occurrence.
Collapse
Affiliation(s)
- B Colavitto
- University of Geneva, Institute for Environmental Sciences, Climatic Change Impacts and Risks in the Anthropocene, Switzerland; CONICET - Universidad de Buenos Aires, Instituto de Estudios Andinos "Don Pablo Groeber" (IDEAN), Buenos Aires, Argentina.
| | - S Allen
- University of Geneva, Institute for Environmental Sciences, Climatic Change Impacts and Risks in the Anthropocene, Switzerland
| | - D Winocur
- Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Departamento de Ciencias Geológicas, Instituto de Estudios Andinos "Don Pablo Groeber" (UBA-CONICET), Buenos Aires, Argentina
| | - A Dussaillant
- Centro de Investigaciones en Ecosistemas de la Patagonia, Coyhaique, Chile; Universidad de Aysén, Coyhaique, Chile; UK Centre for Ecology & Hydrology, Wallingford, United Kingdom
| | - S Guillet
- University of Geneva, Institute for Environmental Sciences, Climatic Change Impacts and Risks in the Anthropocene, Switzerland
| | - A Muñoz-Torrero Manchado
- University of Geneva, Institute for Environmental Sciences, Climatic Change Impacts and Risks in the Anthropocene, Switzerland
| | - S Gorsic
- University of Geneva, Institute for Environmental Sciences, Climatic Change Impacts and Risks in the Anthropocene, Switzerland
| | - M Stoffel
- University of Geneva, Institute for Environmental Sciences, Climatic Change Impacts and Risks in the Anthropocene, Switzerland; Department of Earth Sciences, University of Geneva, Switzerland; Department F.-A. Forel for Environmental and Aquatic Sciences, University of Geneva, Switzerland
| |
Collapse
|
2
|
Guillet S, Crickx E, Azzaoui I, Chappert P, Boutin E, Viallard JF, Rivière E, Gobert D, Galicier L, Malphettes M, Cheze S, Lefrere F, Audia S, Bonnotte B, Lambotte O, Noel N, Fain O, Moulis G, Hamidou M, Gerfaud-Valentin M, Marolleau JP, Terriou L, Martis N, Morin AS, Perlat A, Le Gallou T, Roy-Peaud F, Robbins A, Lega JC, Puyade M, Comont T, Limal N, Languille L, Zarrour A, Luka M, Menager M, Belmondo T, Hue S, Canoui-Poitrine F, Michel M, Godeau B, Mahévas M. Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study. Blood 2023; 141:2867-2877. [PMID: 36893453 DOI: 10.1182/blood.2022018665] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Revised: 01/30/2023] [Accepted: 02/18/2023] [Indexed: 03/11/2023] Open
Abstract
Sustained response off treatment (SROT) after thrombopoietin receptor agonist (TPO-RA) discontinuation has been reported in immune thrombocytopenia (ITP). This prospective multicenter interventional study enrolled adults with persistent or chronic primary ITP and complete response (CR) on TPO-RAs. The primary end point was the proportion of patients achieving SROT (platelet count >30 × 109/L and no bleeding) at week 24 (W24) with no other ITP-specific medications. Secondary end points included the proportion of sustained CR off-treatment (SCROT, platelet count >100 × 109/L and no bleeding) and SROT at W52, bleeding events, and pattern of response to a new course of TPO-RAs. We included 48 patients with a median age of 58.5 years; 30 of 48 had chronic ITP at TPO-RA initiation. In the intention-to-treat analysis, 27 of 48 achieved SROT, 15 of 48 achieved SCROT at W24; 25 of 48 achieved SROT, and 14 of 48 achieved SCROT at W52. No severe bleeding episode occurred in patients who relapsed. Among patients rechallenged with TPO-RA, 11 of 12 achieved CR. We found no significant clinical predictors of SROT at W24. Single-cell RNA sequencing revealed enrichment of a tumor necrosis factor α signaling via NF-κB signature in CD8+ T cells of patients with no sustained response after TPO-RA discontinuation, which was further confirmed by a significant overexpression of CD69 on CD8+ T cells at baseline in these patients as compared with those achieving SCROT/SROT. Our results strongly support a strategy based on progressive tapering and discontinuation of TPO-RAs for patients with chronic ITP who achieved a stable CR on treatment. This trial was registered at www.clinicaltrials.gov as #NCT03119974.
Collapse
Affiliation(s)
- Stéphanie Guillet
- Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Henri Mondor Hôpital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
| | - Etienne Crickx
- Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Henri Mondor Hôpital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
- INSERM U1151/CNRS UMS 8253, Institut Necker Enfants Malades, ATIP-Avenir Team AI2B, Université de Paris Cité, Université Paris-Est Créteil (UPEC), Créteil, France
- INSERM UMR U1163,Imagine Institute, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Université de Paris Cité, Paris, France
| | - Imane Azzaoui
- Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Henri Mondor Hôpital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
- INSERM U1151/CNRS UMS 8253, Institut Necker Enfants Malades, ATIP-Avenir Team AI2B, Université de Paris Cité, Université Paris-Est Créteil (UPEC), Créteil, France
- INSERM U955, Équipe 2, Université Paris-Est Créteil (UPEC), Créteil, France
| | - Pascal Chappert
- INSERM U1151/CNRS UMS 8253, Institut Necker Enfants Malades, ATIP-Avenir Team AI2B, Université de Paris Cité, Université Paris-Est Créteil (UPEC), Créteil, France
- INSERM U955, Équipe 2, Université Paris-Est Créteil (UPEC), Créteil, France
| | - Emmanuelle Boutin
- Unité de Recherche Clinique (Mondor), AP-HP, Henri Mondor Hôpitaux Universitaires, Créteil, France
- INSERM, Institut Mondor de Recherche Biomédicale, Équipe Clinical Epidemiology and Ageing, UPEC, Créteil, France
| | - Jean-François Viallard
- Service de Médecine Interne, Haut-Lévêque Hôpital, Université de Bordeaux, Bordeaux, France
| | - Etienne Rivière
- Service de Médecine Interne, Haut-Lévêque Hôpital, Université de Bordeaux, Bordeaux, France
| | - Delphine Gobert
- Service de Médecine Interne, Saint Antoine Hôpital, AP-HP, Sorbonne Université, Paris, France
| | - Lionel Galicier
- Service d'Immunologie Clinique, Saint Louis Hôpital, AP-HP, Université de Paris Cité, Paris, France
| | - Marion Malphettes
- Service d'Immunologie Clinique, Saint Louis Hôpital, AP-HP, Université de Paris Cité, Paris, France
| | - Stéphane Cheze
- Institut d'Hématologie de Basse-Normandie, Centre Hospitalier de Caen Normandie, Caen, France
| | | | - Sylvain Audia
- Service de Médecine Interne et d'Immunologie Clinique, Centre de Référence Constitutif des Cytopénies Auto-Immunes, Hôpital François Mitterrand, Centre Hospitalier Universitaire (CHU) Dijon-Bourgogne, Dijon, France
| | - Bernard Bonnotte
- Service de Médecine Interne et d'Immunologie Clinique, Centre de Référence Constitutif des Cytopénies Auto-Immunes, Hôpital François Mitterrand, Centre Hospitalier Universitaire (CHU) Dijon-Bourgogne, Dijon, France
| | - Olivier Lambotte
- Service de Médecine Interne et d'Immunologie Clinique, Hôpital Bicêtre, AP-HP, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Nicolas Noel
- Service de Médecine Interne et d'Immunologie Clinique, Hôpital Bicêtre, AP-HP, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Olivier Fain
- Service de Médecine Interne, Saint Antoine Hôpital, AP-HP, Sorbonne Université, Paris, France
| | - Guillaume Moulis
- Service de Médecine Interne, CHU de Toulouse, Toulouse, France
- CIC 1436, Équipe PEPSS, CHU de Toulouse, Toulouse, France
| | | | | | - Jean-Pierre Marolleau
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens-Picardie, Amiens, France
| | - Louis Terriou
- Service de Médecine Interne et d'Immunologie Clinique, CHU de Lille, Lille, France
| | - Nihal Martis
- Service de Médecine Interne et d'Immunologie Clinique, Hôpital de Nice, Nice, France
| | - Anne-Sophie Morin
- Service de Médecine Interne, Jean Verdier Hôpital, AP-HP, Bondy, France
| | - Antoinette Perlat
- Service de Médecine Interne et Immunologie Clinique, CHU de Rennes, Rennes, France
| | - Thomas Le Gallou
- Service de Médecine Interne et Immunologie Clinique, CHU de Rennes, Rennes, France
| | - Frédérique Roy-Peaud
- Service de Médecine Interne-Maladies Infectieuses et Tropicales, CHU de Poitiers, Poitiers, France
| | - Ailsa Robbins
- Department of Internal Medicine, Infectious Diseases, and Clinical Immunology, Robert Debré Hospital, Reims University Hospitals, Reims, France
| | - Jean-Christophe Lega
- Service de Médecine Interne, Hospices Civils de Lyon, Lyon Sud Hôpital, Pierre-Bénite, France
| | - Matthieu Puyade
- Service de Médecine Interne, CHU de Poitiers, Poitiers, France
| | - Thibault Comont
- Service de Médecine Interne, CHU de Toulouse (IUCT-Oncopole), Toulouse, France
| | - Nicolas Limal
- Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Henri Mondor Hôpital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
| | - Laetitia Languille
- Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Henri Mondor Hôpital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
| | - Anissa Zarrour
- Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Henri Mondor Hôpital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
| | - Marine Luka
- Université Paris Cité, Institut Imagine, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, F-75015 Paris, France
| | - Mickael Menager
- Université Paris Cité, Institut Imagine, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, F-75015 Paris, France
| | - Thibault Belmondo
- Département Immunologie-Hématologie, Henri Mondor Hôpital, AP-HP, UPEC, Créteil, France
- UPEC, Faculté de Médecine, Créteil, France
- Service de Santé Publique, AP-HP, Henri Mondor Hôpitaux Universitaires, Créteil, France
| | - Sophie Hue
- Département Immunologie-Hématologie, Henri Mondor Hôpital, AP-HP, UPEC, Créteil, France
- UPEC, Faculté de Médecine, Créteil, France
- INSERM U955, Équipe 16, Institut Mondor de Recherche Biomédicale, UPEC, Créteil, France
| | - Florence Canoui-Poitrine
- Unité de Recherche Clinique (Mondor), AP-HP, Henri Mondor Hôpitaux Universitaires, Créteil, France
- Service de Santé Publique, AP-HP, Henri Mondor Hôpitaux Universitaires, Créteil, France
| | - Marc Michel
- Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Henri Mondor Hôpital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
| | - Bertrand Godeau
- Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Henri Mondor Hôpital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
| | - Matthieu Mahévas
- Service de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Henri Mondor Hôpital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
- INSERM U1151/CNRS UMS 8253, Institut Necker Enfants Malades, ATIP-Avenir Team AI2B, Université de Paris Cité, Université Paris-Est Créteil (UPEC), Créteil, France
- INSERM U955, Équipe 2, Université Paris-Est Créteil (UPEC), Créteil, France
| |
Collapse
|
3
|
Guillet S, Loustau V, Boutin E, Zarour A, Comont T, Souchaud-Debouverie O, Costedoat Chalumeau N, Pan-Petesch B, Gobert D, Cheze S, Viallard JF, Morin AS, Sauvetre G, Cliquennois M, Royer B, Masseau A, Terriou L, Fieschi C, Lambotte O, Girault S, Lioger B, Audia S, Sacre K, Lega JC, Langlois V, Benachi A, Orvain C, Devidas A, Humbert S, Gambier N, Ruivard M, Zarrouk V, Ebbo M, Willems L, Segaux L, Mahevas M, Haddad B, Michel M, Canoui-Poitrine F, Godeau B. Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study. Blood 2023; 141:11-21. [PMID: 36054922 PMCID: PMC10644036 DOI: 10.1182/blood.2022017277] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 07/18/2022] [Accepted: 08/03/2022] [Indexed: 01/10/2023] Open
Abstract
The risk of immune thrombocytopenia (ITP) worsening during pregnancy and neonatal ITP (NITP) have never been prospectively studied. We included 180 pregnant and 168 nonpregnant women with ITP in a prospective, multicenter, observational cohort study. A total of 131 pregnant women with ITP were matched to 131 nonpregnant women with ITP by history of splenectomy, ITP status (no response, response, complete response), and duration. Groups were followed for 15 months. The primary outcome was the first occurrence of ITP worsening defined by a composite end point including bleeding events and/or severe thrombocytopenia (<30 × 109/L) and/or ITP treatment modification. We also studied the recurrence of ITP worsening and the incidence of NITP and risk factors. The first occurrence of ITP worsening did not differ between pregnant and nonpregnant women with ITP (53.4 per 100 person-years [95% confidence interval {CI}, 40.8-69.9] vs 37.1 [95% CI, 27.5-50.0]; hazard ratio {HR}, 1.35 [95% CI, 0.89-2.03], P = .16). Pregnant women with ITP were more likely to have recurrence of severe thrombocytopenia and treatment modification (HR, 2.71 [95% CI, 1.41-5.23], P = .003; HR, 2.01 [95% CI, 1.14-3.57], P = .017, respectively). However, recurrence of severe bleeding events was not different between groups (P = .4). Nineteen (14%) neonates showed NITP <50 × 109/L. By multivariable analysis, NITP was associated with a previous offspring with NITP and maternal platelet count <50 × 109/L within 3 months before delivery (adjusted odds ratio, 5.55 [95% CI, 1.72-17.89], P = .004 and 4.07 [95% CI, 1.41-11.73], P = .009). To conclude, women with ITP do not increase their risk of severe bleeding during pregnancy. NITP is associated with NITP history and the severity of maternal ITP during pregnancy. These results will be useful for counseling women with ITP.
Collapse
MESH Headings
- Infant, Newborn
- Female
- Humans
- Pregnancy
- Purpura, Thrombocytopenic, Idiopathic/epidemiology
- Purpura, Thrombocytopenic, Idiopathic/therapy
- Purpura, Thrombocytopenic, Idiopathic/complications
- Cohort Studies
- Prospective Studies
- Pregnancy Complications, Hematologic/epidemiology
- Pregnancy Complications, Hematologic/therapy
- Thrombocytopenia, Neonatal Alloimmune/therapy
- Retrospective Studies
Collapse
Affiliation(s)
- Stéphanie Guillet
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
| | - Valentine Loustau
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
- Service de Médecine Interne, Centre Hospitalier Alpes Léman, Contamine sur Arve, France
| | - Emmanuelle Boutin
- Unité de Recherche Clinique (URC Mondor), AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
- Univ Paris Est Créteil, INSERM, IMRB, Equipe CEpiA (Clinical Epidemiology and Ageing), Créteil, France
| | - Anissa Zarour
- Unité de Recherche Clinique (URC Mondor), AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - Thibault Comont
- Service de Médecine Interne et d’Immunopathologie–IUCT-Oncopole, CHU de Toulouse, Toulouse, France
| | | | - Nathalie Costedoat Chalumeau
- Service de Médecine Interne, Centre de Référence Maladies Auto-immunes et Systémiques Rares, Hôpital Cochin, AP-HP, Université de Paris, Paris, France
- Centre for Clinical Epidemiology, Hôpital Hôtel-Dieu, AP-HP, Université de Paris, Centre of Research in Epidemiology and Statistics, Paris, France
| | | | - Delphine Gobert
- Service de Médecine Interne, Hôpital Saint Antoine, AP-HP, Sorbonne Université, Paris, France
| | - Stéphane Cheze
- Institut d’Hématologie de Basse-Normandie, Centre Hospitalier de Caen Normandie, Caen, France
| | | | - Anne-Sophie Morin
- Service de Médecine Interne, Hôpital Jean Verdier, AP-HP, Bondy, France
| | - Gaetan Sauvetre
- Service de Médecine Interne, Hôpital Charles Nicolle, Université de Rouen, Rouen, France
| | - Manuel Cliquennois
- Service d'Onco-hématologie Adulte, Hôpital Saint-Vincent de Paul, GH de l'institut Catholique de Lille, Lille, France
| | - Bruno Royer
- Service d’Immuno-hématologie, Hôpital Saint Louis, Paris, France
- Service d’Hématologie clinique, CHU d’Amiens, Amiens, France
| | - Agathe Masseau
- Service de Médecine Interne, CHU de Nantes, Nantes, France
| | - Louis Terriou
- Service de Médecine Interne et d’Immunologie Clinique, CHU Lille, Université de Lille, Lille, France
| | - Claire Fieschi
- Service d’Immunologie Clinique, Hôpital Saint Louis, AP-HP, Paris, France
| | - Olivier Lambotte
- Service de Médecine Interne et d’Immunologie Clinique, Hôpital Bicêtre, Université Paris Sacly, Le Kremlin-Bicêtre, France
| | - Stéphane Girault
- Service d’Hématologie Clinique et de Thérapie Cellulaire, CHU Dupuytren, Limoges, France
| | | | - Sylvain Audia
- Service de Médecine Interne et d’Immunologie Clinique, Centre de Référence Constitutif des Cytopénies Auto-Immunes, Hôpital François Mitterrand, CHU Dijon-Bourgogne, Dijon, France
| | - Karim Sacre
- Service de Médecine Interne, Hôpital Bichat, AP-HP, Paris, France et Université de Paris, Centre de Recherche sur l’Inflammation, INSERM UMR1149, CNRS ERL8252, Laboratoire d’Excellence Inflamex, Paris, France
| | - Jean Christophe Lega
- Service de Médecine Interne et Médecine Vasculaire, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, Université de Lyon, Lyon, France
- Laboratoire de Biométrie et Biologie Évolutive, CNRS-UMR 5588, Université Lyon 1, Lyon, France
| | - Vincent Langlois
- Service de Médecine Interne, Hôpital Jacques Monod, Le Havre, France
| | - Alexandra Benachi
- Service d’Obstétrique et Gynécologie, Hôpital Antoine-Béclère, AP-HP, Université Paris-Saclay, Clamart, France
| | - Corentin Orvain
- Service d’Hématologie, Hôpital d’Anger, INSERM, CRCINA, Université d’Angers, Angers, France
| | - Alain Devidas
- Service d’Hématologie Clinique, CH Sud Francilien, Corbeil Essonnes, France
| | | | - Nicolas Gambier
- Service de Médecine Interne, CH Général Delafontaine, St Denis, France
| | - Marc Ruivard
- Service de Médecine Interne, CHU Estaing, Clermont-Ferrand, France
| | - Virginie Zarrouk
- Service de Médecine Interne, Hôpital Beaujon, AP-HP, Clichy, France
| | - Mikael Ebbo
- Service de Médecine Interne, Hôpital de la Conception, AP-HP, Université Aix-Marseille, Marseille, France
| | - Lise Willems
- Service d’Hématologie Clinique, Hôpital Cochin, Paris, France
| | - Lauriane Segaux
- Service de Santé Publique, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - Matthieu Mahevas
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
| | - Bassam Haddad
- Centre Hospitalier Inter-Communal de Créteil, Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Equipe Immunorégulation et Biothérapie (I-BIOT), Université Paris Est Créteil, Univ Paris Est Créteil, INSERM U955, Institut Mondor De Recherche Biomédicale (IMRB), Créteil, France
| | - Marc Michel
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
| | - Florence Canoui-Poitrine
- Unité de Recherche Clinique (URC Mondor), AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
- Service de Santé Publique, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - Bertrand Godeau
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
| |
Collapse
|
4
|
Daniel A, Ghez D, Ravaiau C, Cavalieri D, Tournilhac O, Herbaux C, Roriz M, Wemeau M, Guillet S, Bossard JB, Hélène D, Kaphan E, Caroline R, Florence L, Pierache A, Michel M, Godeau B, Terriou L. Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma. Eur J Haematol 2022; 109:719-727. [PMID: 36048142 PMCID: PMC9826375 DOI: 10.1111/ejh.13858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2022] [Revised: 08/22/2022] [Accepted: 08/24/2022] [Indexed: 01/11/2023]
Abstract
BACKGROUND Autoimmune conditions in B-cell lymphomas are frequent. Steroids are standard of care, but many patients require other immunosuppressive agents. Ibrutinib is a Bruton Tyrosine Kinase inhibitor that is approved for B-cell indolent lymphoma treatment. We evaluated the use of ibrutinib in previously treated hematologic immune manifestations associated with B-cell lymphomas. RESULTS We conducted a retrospective multicentric observational study. Patients presenting with active, relapsed/refractory B-cell lymphoma associated hematological immune manifestation (autoimmune cytopenia, acquired immune-mediated bleeding disorders) were included. Twenty-five patients were identified. Median age at ibrutinib introduction was 69 years (range 44-84) and median number of previous treatment lines before ibrutinib was 2 (1-7). Twenty-two patients (88%) were on concomitant stable treatment at inclusion. Within a median exposure of 8 months (2-35), overall response rate to ibrutinib on immune manifestations was 76% (95% CI, 54.9-90.6); complete response rate 44%. Fourteen patients (63%) were able to be weaned from concomitant treatments. Fourteen patients (56%) presented treatment-related adverse events, mostly Grade 1 or 2. CONCLUSIONS Ibrutinib in this setting provides good efficacy and safety profile. Clinical trials are needed to define subgroups of patients who will benefit from this strategy and establish its place in the therapeutic arsenal.
Collapse
Affiliation(s)
- Adrien Daniel
- Department of HematologyClaude Huriez University HospitalLilleFrance
| | - David Ghez
- Department of Hematology and INSERM UMR1030Gustave RoussyVillejuifFrance
| | - Camille Ravaiau
- Department of Internal MedicineAngers University HospitalAngersFrance
| | - Doriane Cavalieri
- Department of HematologyEstaing University HospitalClermont‐FerrandFrance
| | - Olivier Tournilhac
- Department of HematologyEstaing University HospitalClermont‐FerrandFrance
| | - Charles Herbaux
- Department of HematologySt Eloi University HospitalMontpellierFrance
| | - Mélanie Roriz
- Department of Internal MedicineAgen‐Nérac HospitalAgenFrance
| | - Mathieu Wemeau
- Department of HematologyVictor Provo HospitalRoubaixFrance
| | - Stéphanie Guillet
- Department of Internal MedicineHenri‐Mondor University Hospital, Assistance Publique des Hôpitaux de ParisParisFrance
| | | | | | - Eleonore Kaphan
- Department of HematologyGrenoble‐Alpes University HospitalGrenobleFrance
| | - Regny Caroline
- Department of HematologyPierre Oudot HospitalBourgoin‐JallieuFrance
| | | | - Adeline Pierache
- Univ.Lille, CHU Lille, ULR 2694—METRICS: évaluation des technologies de santé et des pratiques médicalesLilleFrance
| | - Marc Michel
- Department of Internal MedicineHenri‐Mondor University Hospital, Assistance Publique des Hôpitaux de ParisParisFrance
| | - Bertrand Godeau
- Department of Internal MedicineHenri‐Mondor University Hospital, Assistance Publique des Hôpitaux de ParisParisFrance
| | - Louis Terriou
- Department of Internal Medicine and Clinical ImmunologyUniversity of LilleLilleFrance
| |
Collapse
|
5
|
Marien A, Sedefoglu H, Dubois B, Maljean J, Francis F, Berben G, Guillet S, Morin JF, Fumière O, Debode F. Detection of Alphitobius diaperinus by Real-Time Polymerase Chain Reaction With a Single-Copy Gene Target. Front Vet Sci 2022; 9:718806. [PMID: 35356786 PMCID: PMC8959938 DOI: 10.3389/fvets.2022.718806] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Accepted: 01/10/2022] [Indexed: 01/06/2023] Open
Abstract
Use of edible insects as an alternative source of proteins in food and feed is increasing. These last years, numerous companies in Europe have started producing insects for food and feed purposes. In the European Union, the use of edible insects for human consumption falls within Regulation (EU) No. 2015/2283 on novel foods. For feed, Commission Regulation (EU) 2017/893 authorizes seven insect species as processed animal proteins for aquaculture. Methods of authentication are required to check the conformity of the products. In this study, we propose a real-time polymerase chain reaction (PCR) method for the specific detection of the lesser mealworm (Alphitobius diaperinus), one of the species included in the shortlist of authorized insects. The selected target is the cadherin gene with a single-copy (per haploid genome) illustrated by our experimental evidence. The PCR test amplified a 134-bp fragment of the cadherin gene. The qualitative method was assessed toward several performance criteria. Specificity was checked against 54 insect species next to other animal and plant species. The sensitivity, efficiency, robustness, and transferability of the PCR assay were also successfully tested. Finally, the applicability of the test was assessed on real-life processed samples (industrial meals) of A. diaperinus. The study also showed that there seems to be a huge confusion on the correct labeling of the marketed mealworms. We did not succeed to get Alphitobius laevigatus samples. They all appeared to belong to the A. diaperinus taxon.
Collapse
Affiliation(s)
- Aline Marien
- Quality and Authentication of Agricultural Products Unit, Knowledge and Valorization of Agricultural Products Department, Walloon Agricultural Research Centre, Gembloux, Belgium
- *Correspondence: Aline Marien
| | - Hamza Sedefoglu
- Haute Ecole Louvain-en-Hainaut, Montignies-sur-Sambre, Belgium
| | - Benjamin Dubois
- Quality and Authentication of Agricultural Products Unit, Knowledge and Valorization of Agricultural Products Department, Walloon Agricultural Research Centre, Gembloux, Belgium
| | - Julien Maljean
- Quality and Authentication of Agricultural Products Unit, Knowledge and Valorization of Agricultural Products Department, Walloon Agricultural Research Centre, Gembloux, Belgium
| | - Frédéric Francis
- Functional and Evolutionary Entomology, Gembloux Agro-Bio Tech, ULiège, Gembloux, Belgium
| | - Gilbert Berben
- Quality and Authentication of Agricultural Products Unit, Knowledge and Valorization of Agricultural Products Department, Walloon Agricultural Research Centre, Gembloux, Belgium
| | | | | | - Olivier Fumière
- Quality and Authentication of Agricultural Products Unit, Knowledge and Valorization of Agricultural Products Department, Walloon Agricultural Research Centre, Gembloux, Belgium
| | - Frédéric Debode
- Biological Engineering Unit, Life Sciences Department, Walloon Agricultural Research Centre, Gembloux, Belgium
| |
Collapse
|
6
|
Maisonobe L, Bertinchamp R, Damian L, Gérard L, Berisha M, Guillet S, Fieschi C, Malphettes M, Fadlallah J, Hié M, Dunogué B, De Wilde V, Vandergheynst F, Zafrani L, Grall M, Saada N, Garzaro M, Oksenhendler E, Galicier L, Boutboul D. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort. Br J Haematol 2021; 196:599-605. [PMID: 34585382 DOI: 10.1111/bjh.17868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 09/14/2021] [Accepted: 09/17/2021] [Indexed: 11/30/2022]
Abstract
Idiopathic multicentric Castleman disease (iMCD) is a non-clonal inflammatory lymphoproliferative disorder of unknown origin. Recently, TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) emerged as a singular variant of iMCD in Asia and was associated with a severe course and a poor outcome. The present study describes the first large Western cohort of TAFRO syndrome patients (n = 25) meeting the All Japan TAFRO Syndrome Research Group diagnostic criteria. Characteristics of TAFRO patients were compared to iMCD-not otherwise specified (iMCD-NOS) patients used as a control group (n = 43). Our results show that despite baseline characteristics in accordance with previously reported series, Western TAFRO syndrome patients do not appear to present with a worse outcome than iMCD-NOS patients. There were no significant differences between the two groups regarding treatment choice, response to rituximab (71% vs. 67%) or tocilizumab (69% vs. 91%) in TAFRO and iMCD-NOS, respectively. The two-year overall survival was above 95% in both groups. Limits of inclusion and exclusion criteria for TAFRO definition are also discussed. Our findings raise the question of the singularity of the TAFRO entity in Western countries. The data should promote further research using unsupervised models to identify markers of disease severity in Western cohorts of iMCD patients.
Collapse
Affiliation(s)
- Lucas Maisonobe
- Clinical Immunology Department, Hôpital Saint Louis, Université de Paris, Paris, France
| | - Rémi Bertinchamp
- Clinical Immunology Department, Hôpital Saint Louis, Université de Paris, Paris, France.,National Reference Center for Castleman Disease, Hôpital Saint Louis, Université de Paris, Paris, France
| | - Louise Damian
- Internal Medicine and Infectious Disease Department, Hôpital Jacques Monod, Le Havre, France
| | - Laurence Gérard
- Clinical Immunology Department, Hôpital Saint Louis, Université de Paris, Paris, France.,National Reference Center for Castleman Disease, Hôpital Saint Louis, Université de Paris, Paris, France
| | - Mirlinda Berisha
- National Reference Center for Castleman Disease, Hôpital Saint Louis, Université de Paris, Paris, France
| | - Stéphanie Guillet
- Internal Medicine Department, Hôpital Henri Mondor, Université Paris-Est Créteil, Créteil, France
| | - Claire Fieschi
- Clinical Immunology Department, Hôpital Saint Louis, Université de Paris, Paris, France.,National Reference Center for Castleman Disease, Hôpital Saint Louis, Université de Paris, Paris, France
| | - Marion Malphettes
- Clinical Immunology Department, Hôpital Saint Louis, Université de Paris, Paris, France.,National Reference Center for Castleman Disease, Hôpital Saint Louis, Université de Paris, Paris, France
| | - Jehane Fadlallah
- Clinical Immunology Department, Hôpital Saint Louis, Université de Paris, Paris, France.,National Reference Center for Castleman Disease, Hôpital Saint Louis, Université de Paris, Paris, France
| | - Miguel Hié
- Internal Medicine Department, Hôpital Pitié-Salpétrière, Université Paris Sorbonne, Paris, France
| | - Bertrand Dunogué
- Internal Medicine Department, Hôpital Cochin, Université de Paris, Paris, France
| | - Virginie De Wilde
- Hematology Department, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgique
| | - Frédéric Vandergheynst
- Internal Medicine Department, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgique
| | - Lara Zafrani
- Intensive Care Unit, Hôpital Saint Louis, Université de Paris, Paris, France
| | - Maximilien Grall
- Internal Medicine Department, Hôpital Charles Nicolle, Université de Rouen, Rouen, France
| | - Noémie Saada
- Post-Emergency Unit, Hôpital Henri Mondor, Université Paris-Est Créteil, Créteil, France
| | - Margaux Garzaro
- Clinical Immunology Department, Hôpital Saint Louis, Université de Paris, Paris, France.,National Reference Center for Castleman Disease, Hôpital Saint Louis, Université de Paris, Paris, France
| | - Eric Oksenhendler
- Clinical Immunology Department, Hôpital Saint Louis, Université de Paris, Paris, France.,National Reference Center for Castleman Disease, Hôpital Saint Louis, Université de Paris, Paris, France
| | - Lionel Galicier
- Clinical Immunology Department, Hôpital Saint Louis, Université de Paris, Paris, France.,National Reference Center for Castleman Disease, Hôpital Saint Louis, Université de Paris, Paris, France
| | - David Boutboul
- Clinical Immunology Department, Hôpital Saint Louis, Université de Paris, Paris, France.,National Reference Center for Castleman Disease, Hôpital Saint Louis, Université de Paris, Paris, France.,U976 HIPI, INSIGHT team, Hôpital Saint Louis, Université de Paris, Paris, France
| |
Collapse
|
7
|
Crickx E, Moulis G, Ebbo M, Terriou L, Briantais A, Languille L, Limal N, Guillet S, Michel M, Mahevas M, Godeau B. Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia. Br J Haematol 2021; 195:703-705. [PMID: 34467525 PMCID: PMC8653340 DOI: 10.1111/bjh.17813] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 08/17/2021] [Accepted: 08/18/2021] [Indexed: 01/01/2023]
Affiliation(s)
- Etienne Crickx
- Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Guillaume Moulis
- Department of Internal Medicine, Toulouse University Hospital (CHU de Toulouse), Toulouse, France.,CIC 1436, Toulouse University Hospital (CHU de Toulouse), Toulouse, France.,UMR 1027 Inserm, University of Toulouse, Toulouse, France
| | - Mikael Ebbo
- Department of internal medicine, Hôpital la Timone, Assistance Publique Hôpitaux de Marseille, Aix Marseille Université, Marseille, France
| | - Louis Terriou
- Department of Internal Medecine and Immunology, Claude-Huriez University Hospital, Université Lille Nord de France, Lille, France
| | - Antoine Briantais
- Department of internal medicine, Hôpital la Timone, Assistance Publique Hôpitaux de Marseille, Aix Marseille Université, Marseille, France
| | - Laetitia Languille
- Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Nicolas Limal
- Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Stéphanie Guillet
- Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Marc Michel
- Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Matthieu Mahevas
- Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Bertrand Godeau
- Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| |
Collapse
|
8
|
Guillet S, Loustau V, Zarour A, Boutin E, Comont T, Odile S, Costedoat-Chalumeau N, Pan-Petesch B, Gobert D, Cheze S, Jean-François V, Morin A, Sauvetre G, Cliquennois M, Royer B, Masseau A, Terriou L, Fieschi C, Michel M, Godeau B. Facteurs de risques de thrombopénie immunologique néonatale chez les nouveau-nés de femmes atteintes de purpura thrombopénique immunologique : résultats d’une étude multicentrique prospective. Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
9
|
Fauconneau A, Sokolowsky N, Camus M, Darrigade AS, Guillet S, Jullie ML, Beylot-Barry M, Doutre MS. Acquired cutis laxa associated with neutrophilic urticarial dermatosis. Int J Dermatol 2020; 60:771-772. [PMID: 33226126 DOI: 10.1111/ijd.15314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2020] [Revised: 10/18/2020] [Accepted: 10/22/2020] [Indexed: 11/30/2022]
Affiliation(s)
| | - Nina Sokolowsky
- Department of Dermatology, Hôpital Saint André, Bordeaux, France
| | | | | | | | | | | | | |
Collapse
|
10
|
Churakova Sidorova OV, Corona C, Fonti MV, Guillet S, Saurer M, Siegwolf RTW, Stoffel M, Vaganov EA. Recent atmospheric drying in Siberia is not unprecedented over the last 1,500 years. Sci Rep 2020; 10:15024. [PMID: 32929148 PMCID: PMC7490406 DOI: 10.1038/s41598-020-71656-w] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Accepted: 08/17/2020] [Indexed: 11/26/2022] Open
Abstract
Newly developed millennial δ13C larch tree-ring chronology from Siberia allows reconstruction of summer (July) vapor pressure deficit (VPD) changes in a temperature-limited environment. VPD increased recently, but does not yet exceed the maximum values reconstructed during the Medieval Warm Anomaly. The most humid conditions in the Siberian North were recorded in the Early Medieval Period and during the Little Ice Age. Increasing VPD under elevated air temperature affects the hydrology of these sensitive ecosystems by greater evapotranspiration rates. Further VPD increases will significantly affect Siberian forests most likely leading to drought and forest mortality even under additional access of thawed permafrost water. Adaptation strategies are needed for Siberian forest ecosystems to protect them in a warming world.
Collapse
Affiliation(s)
- O V Churakova Sidorova
- Siberian Federal University, Svobodny pr. 79, Krasnoyarsk, Russian Federation, 660041. .,Institute for Environmental Sciences, University of Geneva, 66 Bvd Carl Vogt, 1205, Geneva, Switzerland.
| | - C Corona
- Geolab, UMR 6042 CNRS, Université Clermont-Auvergne (UCA), 4 rue Ledru, 63057, Clermont-Ferrand, France
| | - M V Fonti
- Siberian Federal University, Svobodny pr. 79, Krasnoyarsk, Russian Federation, 660041.,Swiss Federal Institute for Forest, Snow and Landscape Research WSL, Zürcherstrasse 111, 8903, Birmensdorf, Switzerland
| | - S Guillet
- Institute for Environmental Sciences, University of Geneva, 66 Bvd Carl Vogt, 1205, Geneva, Switzerland
| | - M Saurer
- Swiss Federal Institute for Forest, Snow and Landscape Research WSL, Zürcherstrasse 111, 8903, Birmensdorf, Switzerland
| | - R T W Siegwolf
- Swiss Federal Institute for Forest, Snow and Landscape Research WSL, Zürcherstrasse 111, 8903, Birmensdorf, Switzerland
| | - M Stoffel
- Institute for Environmental Sciences, University of Geneva, 66 Bvd Carl Vogt, 1205, Geneva, Switzerland.,Dendrolab.Ch, Department of Earth Sciences, University of Geneva, Rue des Maraîchers 13, 1205, Geneva, Switzerland.,Department F.-A. Forel for Environmental and Aquatic Sciences, University of Geneva, 66 Bvd Carl Vogt, 1205, Geneva, Switzerland
| | - E A Vaganov
- Siberian Federal University, Svobodny pr. 79, Krasnoyarsk, Russian Federation, 660041.,V.N. Sukachev Institute of Forest SB RAS, Federal Research Center "Krasnoyarsk Science Center SB RAS", 50/28 Akademgorodok, Krasnoyarsk, Russian Federation, 660036
| |
Collapse
|
11
|
Pardini T, Alameda J, Aquila A, Boutet S, Decker T, Gleason AE, Guillet S, Hamilton P, Hayes M, Hill R, Koglin J, Kozioziemski B, Robinson J, Sokolowski-Tinten K, Soufli R, Hau-Riege SP. Erratum: Delayed Onset of Nonthermal Melting in Single-Crystal Silicon Pumped with Hard X Rays [Phys. Rev. Lett. 120, 265701 (2018)]. Phys Rev Lett 2020; 124:129903. [PMID: 32281872 DOI: 10.1103/physrevlett.124.129903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Accepted: 03/04/2020] [Indexed: 06/11/2023]
Abstract
This corrects the article DOI: 10.1103/PhysRevLett.120.265701.
Collapse
|
12
|
Nunes JPF, Ledbetter K, Lin M, Kozina M, DePonte DP, Biasin E, Centurion M, Crissman CJ, Dunning M, Guillet S, Jobe K, Liu Y, Mo M, Shen X, Sublett R, Weathersby S, Yoneda C, Wolf TJA, Yang J, Cordones AA, Wang XJ. Liquid-phase mega-electron-volt ultrafast electron diffraction. Struct Dyn 2020; 7:024301. [PMID: 32161776 PMCID: PMC7062553 DOI: 10.1063/1.5144518] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/01/2020] [Accepted: 02/13/2020] [Indexed: 05/23/2023]
Abstract
The conversion of light into usable chemical and mechanical energy is pivotal to several biological and chemical processes, many of which occur in solution. To understand the structure-function relationships mediating these processes, a technique with high spatial and temporal resolutions is required. Here, we report on the design and commissioning of a liquid-phase mega-electron-volt (MeV) ultrafast electron diffraction instrument for the study of structural dynamics in solution. Limitations posed by the shallow penetration depth of electrons and the resulting information loss due to multiple scattering and the technical challenge of delivering liquids to vacuum were overcome through the use of MeV electrons and a gas-accelerated thin liquid sheet jet. To demonstrate the capabilities of this instrument, the structure of water and its network were resolved up to the 3 rd hydration shell with a spatial resolution of 0.6 Å; preliminary time-resolved experiments demonstrated a temporal resolution of 200 fs.
Collapse
Affiliation(s)
- J P F Nunes
- Department of Physics and Astronomy, University of Nebraska-Lincoln, Lincoln, Nebraska 68588, USA
| | | | - M Lin
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - M Kozina
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - D P DePonte
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - E Biasin
- Stanford PULSE Institute, SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - M Centurion
- Department of Physics and Astronomy, University of Nebraska-Lincoln, Lincoln, Nebraska 68588, USA
| | - C J Crissman
- Department of Applied Physics, Stanford University, Stanford, California 94305, USA
| | - M Dunning
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - S Guillet
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - K Jobe
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - Y Liu
- Department of Physics and Astronomy, Stony Brook University, Stony Brook, New York 11794, USA
| | - M Mo
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - X Shen
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - R Sublett
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - S Weathersby
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - C Yoneda
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - T J A Wolf
- Stanford PULSE Institute, SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | | | - A A Cordones
- Stanford PULSE Institute, SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - X J Wang
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| |
Collapse
|
13
|
Larsabal M, Ly S, Sbidian E, Moyal‐Barracco M, Dauendorffer J, Dupin N, Richard M, Chosidow O, Beylot‐Barry M, Abdo I, Acquitter M, Breteque Mignot MA, Amici J, Archier E, Aubin F, Barthelemy H, Baubion E, Beneton N, Bolac C, Bouilly D, Bourseau‐Quetier C, Brenaut E, Buzenet C, Camus M, Celerier P, Chabbert C, Chamaillard M, Charles S, Darrigade A, Delarue M, Depaire F, Devaux S, Do‐Pham G, Duval‐Modeste A, Fabre F, Fauconneau A, Fite C, Fleuret C, Girard C, Grande S, Guillet S, Hacard F, Hegazy S, Hosteing S, Jacquin M, Jegou M, Joly P, Jouary T, Julien D, Kemula M, Kostrzewa E, Lacour J, Legrain V, Livideanu C, Lu D, Maccari F, Magne F, Martin C, Meunier L, Misery L, Parier J, Pelletier F, Perrussel M, Petit‐Fauconneau A, Peyrot I, Plantin P, Pruvost‐Balland C, Regnier E, Reynier‐Rezzi J, Salzes C, Seneschal J, Shollhammer M, Souteyrand A, Staumont D, Toulemonde A, Vanhaecke C, Vedie A, Versapuech J, Vigan M, Viguier M, Villani A. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br J Dermatol 2018; 180:647-656. [DOI: 10.1111/bjd.17147] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/31/2018] [Indexed: 12/01/2022]
Affiliation(s)
- M. Larsabal
- Department of Dermatology Bordeaux University Hospital Bordeaux University Bordeaux France
| | - S. Ly
- Department of Dermatology Bordeaux University Hospital Bordeaux University Bordeaux France
- Vulvology Study Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Psoriasis Research Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
| | - E. Sbidian
- Psoriasis Research Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Department of Dermatology Henri‐Mondor Hospital, Public Assistance – Paris Hospitals (AP‐HP) CréteilFrance
- Virus,Immunity and Cancer University‐Hospital Complex (DHU VIC) EA 7379 Epidemiology in Dermatology and Evaluation of Treatments (EpiDermE) Paris‐Est University Créteil (UPEC) CréteilFrance
| | - M. Moyal‐Barracco
- Vulvology Study Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Department of Dermatology Cochin Tarnier Hospital Paris Descartes University ParisFrance
| | - J.‐N. Dauendorffer
- Vulvology Study Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Psoriasis Research Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Department of Dermatology Saint‐Louis Hospital Paris France
| | - N. Dupin
- Department of Dermatology Cochin Tarnier Hospital Paris Descartes University ParisFrance
- Dermatological Infectiology and Sexually Transmitted Diseases Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
| | - M.A. Richard
- Psoriasis Research Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Department of Dermatology Timone Hospital, Public Assistance–Marseille Hospitals Aix‐Marseille University UMR 911, INSERM CRO2, “Centre de recherche en oncologie biologique et oncopharmacologie” Marseille France
| | - O. Chosidow
- Psoriasis Research Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
- Department of Dermatology Henri‐Mondor Hospital, Public Assistance – Paris Hospitals (AP‐HP) CréteilFrance
- Virus,Immunity and Cancer University‐Hospital Complex (DHU VIC) EA 7379 Epidemiology in Dermatology and Evaluation of Treatments (EpiDermE) Paris‐Est University Créteil (UPEC) CréteilFrance
- Dermatological Infectiology and Sexually Transmitted Diseases Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
| | - M. Beylot‐Barry
- Department of Dermatology Bordeaux University Hospital Bordeaux University Bordeaux France
- Psoriasis Research Group of the French Society for Dermatology Maison de la Dermatologie Malherbes Paris France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Pardini T, Alameda J, Aquila A, Boutet S, Decker T, Gleason AE, Guillet S, Hamilton P, Hayes M, Hill R, Koglin J, Kozioziemski B, Robinson J, Sokolowski-Tinten K, Soufli R, Hau-Riege SP. Delayed Onset of Nonthermal Melting in Single-Crystal Silicon Pumped with Hard X Rays. Phys Rev Lett 2018; 120:265701. [PMID: 30004754 DOI: 10.1103/physrevlett.120.265701] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Revised: 03/30/2018] [Indexed: 05/07/2023]
Abstract
In this work, we monitor the onset of nonthermal melting in single-crystal silicon by implementing an x-ray pump-x-ray probe scheme. Using the ultrashort pulses provided by the Linac Coherent Light Source (SLAC) and a custom-built split-and-delay line for hard x rays, we achieve the temporal resolution needed to detect the onset of the transition. Our data show no loss of long-range order up to 150±40 fs from photoabsorption, which we interpret as the time needed for the electronic system to equilibrate at or above the critical nonthermal melting temperature. Once such equilibration is reached, the loss of long-range atomic order proceeds inertially and is completed within 315±40 fs from photoabsorption.
Collapse
Affiliation(s)
- T Pardini
- Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, California 94550, USA
| | - J Alameda
- Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, California 94550, USA
| | - A Aquila
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - S Boutet
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - T Decker
- Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, California 94550, USA
| | - A E Gleason
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
- Shock and Detonation Physics, Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, New Mexico 87545, USA
| | - S Guillet
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - P Hamilton
- Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, California 94550, USA
| | - M Hayes
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - R Hill
- Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, California 94550, USA
| | - J Koglin
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - B Kozioziemski
- Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, California 94550, USA
| | - J Robinson
- Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, California 94550, USA
| | - K Sokolowski-Tinten
- Faculty of Physics and Center for Nanointegration Duisburg-Essen (CENIDE), University of Duisburg-Essen, Lotharstrasse 1, 47048 Duisburg, Germany
| | - R Soufli
- Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, California 94550, USA
| | - S P Hau-Riege
- Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, California 94550, USA
| |
Collapse
|
15
|
Dequidt L, Cogrel O, Guillet S, Milpied B, Darrigade A, Beylot‐Barry M, Pham‐Ledard A. Paradoxical psoriasiform reactions to antitumour necrosis factor‐α drugs in hidradenitis suppurativa. Br J Dermatol 2017; 178:281-283. [DOI: 10.1111/bjd.15616] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- L. Dequidt
- Dermatology Department University Hospital of Bordeaux Bordeaux France
| | - O. Cogrel
- Dermatology Department University Hospital of Bordeaux Bordeaux France
| | - S. Guillet
- Dermatology Department University Hospital of Bordeaux Bordeaux France
| | - B. Milpied
- Dermatology Department University Hospital of Bordeaux Bordeaux France
| | - A.S. Darrigade
- Dermatology Department University Hospital of Bordeaux Bordeaux France
| | - M. Beylot‐Barry
- Dermatology Department University Hospital of Bordeaux Bordeaux France
| | - A. Pham‐Ledard
- Dermatology Department University Hospital of Bordeaux Bordeaux France
| |
Collapse
|
16
|
Jacquemin C, Rambert J, Guillet S, Thiolat D, Boukhedouni N, Doutre MS, Darrigade AS, Ezzedine K, Blanco P, Taieb A, Boniface K, Seneschal J. Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis. Br J Dermatol 2017; 177:1367-1375. [PMID: 28380264 DOI: 10.1111/bjd.15550] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/31/2017] [Indexed: 12/20/2022]
Abstract
BACKGROUND Plasmacytoid dendritic cells (pDCs) are a subset of dendritic cells specialized in the production of type I interferon (IFN-α/β) and involved in various cutaneous inflammatory and autoimmune disorders, such as cutaneous lupus erythematosus (CLE) and vitiligo. Heat shock proteins (HSPs) are molecular chaperones essential for maintaining cellular functions, but they can act as a danger signal during inflammation. OBJECTIVES To decipher the role of HSP70 in the production of IFN-α by pDCs in CLE and vitiligo. METHODS Expression of HSP70 and CD123+ pDCs was analysed by immunohistochemistry or immunofluorescence in CLE and vitiligo skin samples. Flow cytometry was performed to analyse expression of HSP70 receptors, activation markers on pDCs and DNA uptake by pDCs in the presence of HSP70. The impact of HSP70 on DNA-induced IFN-α secretion by pDCs was evaluated by enzyme-linked immunosorbent assay (ELISA). The effect of IFN-α on chemokine (C-X-C motif) ligand 9 (CXCL9)/10 gene and protein expression by keratinocytes was determined by real-time polymerase chain reaction and ELISA. RESULTS Infiltration of pDCs in CLE and progressive vitiligo was primarily located in the epidermis, close to keratinocytes expressing HSP70. In vitro experiments revealed that the pDCs expressing HSP70 receptor Lox-1 (lectin-like oxidized low-density lipoprotein-receptor-1) were able to aggregate HSP70. Exogenous HSP70 induced activation of pDCs and increased the uptake of exogenous DNA. Furthermore, HSP70 potentiated DNA-induced IFN-α production by pDCs. Finally, IFN-α induced expression of CXCL9 and CXCL10 by keratinocytes. CONCLUSIONS These data demonstrate that interaction between HSP70 and pDCs in CLE and vitiligo is a prerequisite for the enhancement of IFN-α production, and could be an interesting target.
Collapse
Affiliation(s)
- C Jacquemin
- INSERM U1035, BMGIC, Immuno-dermatology ATIP-AVENIR, Bordeaux, France
| | | | - S Guillet
- Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France
| | - D Thiolat
- INSERM U1035, BMGIC, Immuno-dermatology ATIP-AVENIR, Bordeaux, France
| | - N Boukhedouni
- INSERM U1035, BMGIC, Immuno-dermatology ATIP-AVENIR, Bordeaux, France
| | - M-S Doutre
- Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France
| | - A-S Darrigade
- Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France
| | - K Ezzedine
- Department of Dermatology, AP-HP, Hôpital Henri-Mondor, Créteil, France
| | - P Blanco
- CNRS/UMR 5164, Immuno ConcEpT, University of Bordeaux, Bordeaux, France
| | - A Taieb
- INSERM U1035, BMGIC, Immuno-dermatology ATIP-AVENIR, Bordeaux, France.,Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France
| | - K Boniface
- INSERM U1035, BMGIC, Immuno-dermatology ATIP-AVENIR, Bordeaux, France
| | - J Seneschal
- INSERM U1035, BMGIC, Immuno-dermatology ATIP-AVENIR, Bordeaux, France.,Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France
| |
Collapse
|
17
|
Dequidt L, Cogrel O, Guillet S, Milpied B, Darrigade AS, Seneschal J, Beylot-Barry M, Pham-Ledard A. Des réactions paradoxales cutanées psoriasiformes atypiques induites par les anti-TNFα dans l’hidradénite suppurée. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.128] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Blaizot R, Cogrel O, Fernandez P, Guillet S, Fauconneau A, Beylot-Barry M, Pham-Ledard A. L’ostéite : une complication rare de l’hidradénite suppurée périnéale. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
19
|
Scherlinger M, Guillet S, Doutre MS, Beylot-Barry M, Pham-Ledard A. Pyoderma gangrenosum with extensive pulmonary involvement. J Eur Acad Dermatol Venereol 2016; 31:e214-e216. [DOI: 10.1111/jdv.13976] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- M. Scherlinger
- Dermatology Department; CHU de Bordeaux; Bordeaux France
| | - S. Guillet
- Dermatology Department; CHU de Bordeaux; Bordeaux France
| | - M.-S. Doutre
- Dermatology Department; CHU de Bordeaux; Bordeaux France
| | | | - A. Pham-Ledard
- Dermatology Department; CHU de Bordeaux; Bordeaux France
| |
Collapse
|
20
|
Jacquemin C, Guillet S, Rambert J, Thiolat D, Ezzedine K, Blanco P, Bertolotti A, Taieb A, Boniface K, Seneschal J. 366 HSP70 enhances the production of interferon-alpha by plasmacytoid dendritic cells: Relevance for cutaneous lupus and vitiligo pathogenesis. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
21
|
Blaizot R, Dutkiewicz AS, Guillet S, Pham-Ledard A, Beylot-Barry M. Intravenous cidofovir for diffuse genital warts in the setting of multifactorial immunosuppression. J Eur Acad Dermatol Venereol 2016; 31:e162-e163. [DOI: 10.1111/jdv.13880] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- R. Blaizot
- Dermatology Department; Oncodermatology Unit; CHU de Bordeaux; University of Bordeaux; Bordeaux France
| | - A.-S. Dutkiewicz
- Dermatology Department; Oncodermatology Unit; CHU de Bordeaux; University of Bordeaux; Bordeaux France
| | - S. Guillet
- Dermatology Department; Oncodermatology Unit; CHU de Bordeaux; University of Bordeaux; Bordeaux France
| | - A. Pham-Ledard
- Dermatology Department; Oncodermatology Unit; CHU de Bordeaux; University of Bordeaux; Bordeaux France
| | - M. Beylot-Barry
- Dermatology Department; Oncodermatology Unit; CHU de Bordeaux; University of Bordeaux; Bordeaux France
| |
Collapse
|
22
|
Guillet S, Gérard L, Meignin V, Agbalika F, Cuccini W, Denis B, Katlama C, Galicier L, Oksenhendler E. Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution. Am J Hematol 2016; 91:233-7. [PMID: 26799611 DOI: 10.1002/ajh.24251] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Revised: 10/24/2015] [Accepted: 11/18/2015] [Indexed: 11/10/2022]
Abstract
Human immunodeficiency virus (HIV)-associated primary effusion lymphoma (PEL) is a rare B-cell non-Hodgkin lymphoma with poor prognosis. Lymphoma cells are always infected with human herpesvirus-8 (HHV-8) and in most cases coinfected with Epstein-Barr virus. In classic presentation, PEL is characterized by body cavity effusions with or without mass lesions. A variant with only extracavitary localization has also been described. We report on a large single-center series of patients with PEL in the era of combined antiretroviral therapy (cART). The main objective was to compare the characteristics and the outcome of patients with classic (n = 34) and extracavitary (n = 17) variant PEL. At PEL diagnosis, no major difference was observed between the two groups in terms of demographic and HIV characteristics. Extracavitary localizations were exclusively nodal in six patients and involved various organs in 11 patients. Another HHV-8-associated disease was observed in 31 patients, Kaposi sarcoma in 25, and multicentric Castleman disease in 18 patients, without difference between the two groups. Thirty-two patients were treated with CHOP associated with high-dose methotrexate, 13 were treated with CHOP-derived regimen alone, and six patients received low-dose/no chemotherapy. Complete remission was achieved in 21 (62%) and seven (41%) patients of the classic and extracavitary groups, respectively. The median overall survival (OS) was 10.2 months. Despite a higher disease-free survival in the extracavitary group, there was no difference in OS between the two variants. Based on this series, characteristics of classic and extracavitary variants were very close. Although prognosis of PEL remains very severe in cART era, the median survival compares favorably with earlier series.
Collapse
Affiliation(s)
- Stéphanie Guillet
- Department of Clinical Immunology; Saint-Louis Hospital, AP-HP; Paris France
| | - Laurence Gérard
- Department of Clinical Immunology; Saint-Louis Hospital, AP-HP; Paris France
- EA3518, University Paris Diderot; Paris France
| | - Véronique Meignin
- EA3518, University Paris Diderot; Paris France
- Department of Pathology; Saint-Louis Hospital, AP-HP; Paris France
| | - Felix Agbalika
- EA3518, University Paris Diderot; Paris France
- Virology Laboratory, Saint-Louis Hospital, AP-HP; Paris France
| | - Wendy Cuccini
- Hematology Laboratory, Saint-Louis Hospital, AP-HP; Paris France
| | - Blandine Denis
- Department of Infectious Diseases; Saint-Louis Hospital, AP-HP; Paris France
| | - Christine Katlama
- Department of Infectious Diseases; Pitié-Salpêtrière Hospital, AP-HP; Paris France
| | - Lionel Galicier
- Department of Clinical Immunology; Saint-Louis Hospital, AP-HP; Paris France
- EA3518, University Paris Diderot; Paris France
| | - Eric Oksenhendler
- Department of Clinical Immunology; Saint-Louis Hospital, AP-HP; Paris France
- EA3518, University Paris Diderot; Paris France
| |
Collapse
|
23
|
Blaizot R, Biscay P, Guillet S, Dutkiewicz AS, Pham-Ledard A, Beylot-Barry M. Efficacité du cidofovir intraveineux pour des condylomes ano-génitaux dans un contexte d’immunodépression multifactorielle. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Scherlinger M, Guillet S, Dutkiewicks AS, Beylot-Barry M, Doutre MS, Pham-Ledard A. Atteinte pulmonaire au cours d’un pyoderma gangrenosum. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Guillet S, Rambert J, Lucchese F, Thiolat D, Blanco P, Taieb A, Boniface K, Seneschal J. Implication de la protéine de choc thermique HSP72 dans l’activation des cellules dendritiques plasmacytoïdes au cours du lupus érythémateux cutané. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
26
|
Guillet S, Rambert J, Lucchese F, Thiolat D, Blanco P, Taieb A, Boniface K, Seneschal J. La protéine de choc thermique HSP72 potentialise l’activation des cellules dendritiques plasmacytoïdes dans le lupus érythémateux. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.04.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Jouary T, Guillet S, Droitcourt C, Dutriaux C, Ezzedine K, Goussot JF, Taieb A. Lichen sclerosus mimicking halo-naevus comedonicus. J Eur Acad Dermatol Venereol 2014; 30:375-6. [PMID: 25354312 DOI: 10.1111/jdv.12800] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- T Jouary
- Service de Dermatologie, Hôpital Saint André, Bordeaux, France
| | - S Guillet
- Service de Dermatologie, Hôpital Saint André, Bordeaux, France
| | - C Droitcourt
- Service de Dermatologie, Hôpital Saint André, Bordeaux, France
| | - C Dutriaux
- Service de Dermatologie, Hôpital Saint André, Bordeaux, France
| | - K Ezzedine
- Service de Dermatologie, Hôpital Saint André, Bordeaux, France
| | - J F Goussot
- Service d'Anatomopathologie, Hôpital Haut-Lévêque, Pessac, France
| | - A Taieb
- Service de Dermatologie, Hôpital Saint André, Bordeaux, France
| |
Collapse
|
28
|
Barennes H, Guillet S, Limsreng S, Him S, Nouhin J, Hak C, Srun C, Viretto G, Ouk V, Delfraissy JF, Ségéral O. Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia. PLoS One 2014; 9:e105736. [PMID: 25166019 PMCID: PMC4148321 DOI: 10.1371/journal.pone.0105736] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2014] [Accepted: 07/28/2014] [Indexed: 11/19/2022] Open
Abstract
Introduction In resource limited settings, patients entering an antiretroviral therapy (ART) program comprise ART naive and ART pre-treated patients who may show differential virological outcomes. Methods This retrospective study, conducted in 2010–2012 in the HIV clinic of Calmette Hospital located in Phnom Penh (Cambodia) assessed virological failure (VF) rates and patterns of drug resistance of naive and pre-treated patients. Naive and ART pre-treated patients were included when a Viral Load (VL) was performed during the first year of ART for naive subjects or at the first consultation for pre-treated individuals. Patients showing Virological failure (VF) (>1,000 copies/ml) underwent HIV DR genotyping testing. Interpretation of drug resistance mutations was done according to 2013 version 23 ANRS algorithms. Results On a total of 209 patients, 164 (78.4%) were naive and 45 (21.5%) were ART pre-treated. Their median initial CD4 counts were 74 cells/mm3 (IQR: 30–194) and 279 cells/mm3 (IQR: 103–455) (p<0.001), respectively. Twenty seven patients (12.9%) exhibited VF (95% CI: 8.6–18.2%), including 10 naive (10/164, 6.0%) and 17 pre-treated (17/45, 37.8%) patients (p<0.001). Among these viremic patients, twenty-two (81.4%) were sequenced in reverse transcriptase and protease coding regions. Overall, 19 (86.3%) harbored ≥1 drug resistance mutations (DRMs) whereas 3 (all belonging to pre-treated patients) harbored wild-types viruses. The most frequent DRMs were M184V (86.3%), K103N (45.5%) and thymidine analog mutations (TAMs) (40.9%). Two (13.3%) pre-treated patients harbored viruses that showed a multi-nucleos(t)ide resistance including Q151M, K65R, E33A/D, E44A/D mutations. Conclusion In Cambodia, VF rates were low for naive patients but the emergence of DRMs to NNRTI and 3TC occurred relatively quickly in this subgroup. In pre-treated patients, VF rates were much higher and TAMs were relatively common. HIV genotypic assays before ART initiation and for ART pre-treated patients infection should be considered as well.
Collapse
Affiliation(s)
- Hubert Barennes
- Agence Nationale de Recherche sur le VIH et les Hepatites (ANRS), Phnom Penh, Cambodia
- ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Univ. Bordeaux, Bordeaux, France
- Epidemiology Unit, Pasteur Institute, Phnom Penh, Cambodia
- * E-mail:
| | - Stéphanie Guillet
- Agence Nationale de Recherche sur le VIH et les Hepatites (ANRS), Phnom Penh, Cambodia
- Assistance Publique - Hôpitaux de Paris (AP-HP), Département de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre, France
| | | | - Sovanvatey Him
- Hospital Calmette, Phnom Penh, Cambodia
- Ensemble pour une Solidarité Thérapeutique Hospitalière En Réseau (ESTHER), Phnom Penh, Cambodia
| | - Janin Nouhin
- HIV/Hepatitis Unit, Pasteur Institute, Phnom Penh, Cambodia
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Chanroeurn Hak
- Hospital Calmette, Phnom Penh, Cambodia
- Ensemble pour une Solidarité Thérapeutique Hospitalière En Réseau (ESTHER), Phnom Penh, Cambodia
| | | | - Gerald Viretto
- Ensemble pour une Solidarité Thérapeutique Hospitalière En Réseau (ESTHER), Phnom Penh, Cambodia
| | - Vara Ouk
- Hospital Calmette, Phnom Penh, Cambodia
- Ensemble pour une Solidarité Thérapeutique Hospitalière En Réseau (ESTHER), Phnom Penh, Cambodia
| | - Jean Francois Delfraissy
- Assistance Publique - Hôpitaux de Paris (AP-HP), Département de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre, France
- Ensemble pour une Solidarité Thérapeutique Hospitalière En Réseau (ESTHER), Phnom Penh, Cambodia
| | - Olivier Ségéral
- Assistance Publique - Hôpitaux de Paris (AP-HP), Département de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre, France
- Ensemble pour une Solidarité Thérapeutique Hospitalière En Réseau (ESTHER), Phnom Penh, Cambodia
| |
Collapse
|
29
|
Guillet S, Hirsch P, Marzac C, Mohty M, Marie JP, Legrand O. Long-term imatinib maintenance therapy for adult Philadelphia positive acute lymphoblastic leukemia. Leuk Lymphoma 2014; 55:2646-8. [PMID: 24491028 DOI: 10.3109/10428194.2014.889828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Stéphanie Guillet
- Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint-Antoine, Assistance Publique - Hôpitaux de Paris , Paris , France
| | | | | | | | | | | |
Collapse
|
30
|
Guillet S, Fauconneau A, Pham-Ledard AL, Vergier B, Beylot-Barry M, Doutre MS, Cogrel O. Kératoacanthome sous-unguéal : étude anatomoclinique, immuno-histochimique et prise en charge chirurgicale de cinq cas. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
31
|
Ezzedine K, Belin E, Guillet S, D'Almeida M, Droitcourt C, Accocebery I, Milpied B, Jouary T, Malvy D, Taieb A. Cutaneous hyphomycosis due to Paecilomyces lilacinus. Acta Derm Venereol 2012; 92:156-7. [PMID: 22002343 DOI: 10.2340/00015555-1179] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
32
|
Seneschal J, Guillet S, Ezzedine K, Taïeb A, Milpied B. Alternative Procedure to Allow Continuation of Dapsone Therapy despite Serious Adverse Reaction in a Case of Dapsone-Sensitive Erythema Elevatum Diutinum. Dermatology 2012; 224:115-9. [DOI: 10.1159/000337424] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2011] [Accepted: 02/08/2012] [Indexed: 11/19/2022] Open
|
33
|
Guillet S, Séneschal J, Milpied B, Ezzedine K, Taïeb A. Erythema elevatum diutinum et induction de tolérance à la dapsone : à propos d’un cas. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.10.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Guillet S, Stokkermans J, Doutre M, Beylot-Barry M. Dermatose neutrophilique aiguë pustuleuse compliquant un mycosis fongoïde transformé. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.10.293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
35
|
Kostine M, Guillet S, Ribeiro E, Dieval C, Duffau P, Mercie P, Longy-Boursier M. Polyarthrite destructrice révélant un TRAPS ? Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
36
|
Ezzedine K, Solé G, Guillet S, Belin E, Droitcourt C, Jouary T, Taieb A. An extraordinary ‘sunburn’ in a black patient. Br J Dermatol 2011; 164:1398-400. [DOI: 10.1111/j.1365-2133.2011.10255.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Pan G, French D, Mao W, Maruoka M, Risser P, Lee J, Foster J, Aggarwal S, Nicholes K, Guillet S, Schow P, Gurney AL. Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice. J Immunol 2001; 167:6559-67. [PMID: 11714825 DOI: 10.4049/jimmunol.167.11.6559] [Citation(s) in RCA: 145] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
IL-17 is a proinflammatory cytokine, and its in vivo expression induces neutrophilia in mice. IL-17E is a recently described member of an emerging family of IL-17-related cytokines. IL-17E has been shown to bind IL-17Rh1, a protein distantly related to the IL-17R, suggesting that IL-17E probably possesses unique biological functions. In this study, we have identified the murine ortholog of IL-17E and developed transgenic mice to characterize its actions in vivo. Biological consequences of overexpression of murine (m)IL-17E, both unique to IL-17E and similar to IL-17, were revealed. Exposure to mIL-17E resulted in a Th2-biased response, characterized by eosinophilia, increased serum IgE and IgG1, and a Th2 cytokine profile including elevated serum levels of IL-13 and IL-5 and elevated gene expression of IL-4, IL-5, IL-10, and IL-13 was observed in many tissues. Increased gene expression of IFN-gamma in several tissues and elevated serum TNF-alpha were also noted. In addition, IL-17E induces G-CSF production in vitro and mIL-17E-transgenic mice had increased serum G-CSF and exhibit neutrophilia, a property shared by IL-17. Moreover, exposure to mIL-17E elicited pathological changes in multiple tissues, particularly liver, heart, and lungs, characterized by mixed inflammatory cell infiltration, epithelial hyperplasia, and hypertrophy. Taken together, these findings suggest that IL-17E is a unique pleiotropic cytokine and may be an important mediator of inflammatory and immune responses.
Collapse
Affiliation(s)
- G Pan
- Department of Molecular Oncology, Genentech, Inc., South San Francisco, CA 94080, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Guillet S, Guiller A, Deunff J, Vancassel M. Analysis of a contact zone in the Forficula auricularia L. (Dermaptera: Forficulidae) species complex in the Pyrenean Mountains. Heredity (Edinb) 2000; 85 Pt 5:444-9. [PMID: 11122422 DOI: 10.1046/j.1365-2540.2000.00775.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The taxon Forficula auricularia L. (Dermaptera: Forficulidae) is a complex of two sibling species that differ in life history (number of clutches per year and imaginal diapause) and that have diverged at the molecular level. The study of a contact zone in the Pyrenean Mountains, using the PCR-RFLP method on two mitochondrial regions (the 16S rRNA and the Cytochrome Oxidase intergenic region), revealed the coexistence of the sibling species at intermediate altitude (1200 m) whereas at lower and higher altitudes only one species was found. An allozyme study, conducted simultaneously and based on four polymorphic loci (PGI1, AAT1, Est-P1 and Est-P2), showed no sign of nuclear introgression. The apparent lack of hybridization in the field is consistent with a postzygotic barrier observed in the laboratory (a nearly complete failure to produce F(1) hybrids). This contact zone is probably a sympatric zone between two genetically differentiated species.
Collapse
Affiliation(s)
- S Guillet
- UMR CNRS 6553, Université dé Rennes I, Bat. 14, Campus de Beaulieu, Avenue du Général Leclerc, 35042 Rennes cedex, France.
| | | | | | | |
Collapse
|
39
|
Affiliation(s)
- S Guillet
- UMR CNRS 6553 Ecobio, Universite de Rennes 1, Batiment 14, Campus de Beaulieu, Avenue General Leclerc, 35042 Rennes, France.
| | | |
Collapse
|